Nitric Oxide Dysregulation and Vaso-Occlusive Crisis in Sickle Cell Anemia: A Review
International Journal of Medical Sciences and Pharma Research · 2024
DOI: 10.22270/ijmspr.v10i2.99 ↗Abstract
Sickle cell anemia (SCA) is a genetic disorder characterized by the production of abnormal hemoglobin S (HbS), leading to chronic hemolysis and recurrent vaso-occlusive crises (VOCs). VOCs are acute, painful episodes caused by the obstruction of blood flow due to sickled red blood cells (RBCs), resulting in tissue ischemia and organ damage. Nitric oxide (NO) plays a crucial role in vascular homeostasis, and its dysregulation is a significant factor in the pathophysiology of SCA, particularly in VOCs. In SCA, chronic hemolysis releases free hemoglobin into the plasma, which scavenges NO and reduces its bioavailability. Additionally, increased arginase activity depletes L-arginine, the substrate for NO synthesis, further diminishing NO production. Oxidative stress exacerbates NO degradation and endothelial dysfunction, amplifying the risk of VOCs. The interplay between NO deficiency, oxidative stress, and endothelial dysfunction creates a vicious cycle that perpetuates vascular damage and increases the frequency and severity of VOCs. This review explores the mechanisms underlying NO dysregulation in SCA and its impact on vascular function. It also discusses potential therapeutic interventions aimed at modulating NO pathways to prevent or reduce VOCs. These interventions include NO donors, L-arginine supplementation, phosphodiesterase inhibitors, antioxidant therapy, and arginase inhibitors. Keywords: Sickle cell anemia, vaso-occlusive crisis, nitric oxide dysregulation, hemolysis, endothelial dysfunction, oxidative stress, therapeutic interventions.
EUVIMED